Search Results - "De Gislain, C."

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma by Mornex, F, Thomas, L, Mohr, P, Hauschild, A, Delaunay, M M, Lesimple, T, Tilgen, W, Bui, B N, Guillot, B, Ulrich, J, Bourdin, S, Mousseau, M, Cupissol, D, Bonneterre, M E, De Gislain, C, Bensadoun, R J, Clavel, M

“…The main objective of this prospective multicentre randomized phase III study was to compare a combined regimen of fotemustine plus whole brain irradiation…”
Get full text

Male breast cancer: Results of the treatments and prognostic factors in 397 cases by Cutuli, B., Lacroze, M., Dilhuydy, J.M., Veiten, M., De Lafontan, B., Marchal, C., Resbeut, M., Graic, Y., Campana, F., Moncho-Bernier, V., De Gislain, C., Tortochaux, J., Cuillere, J.C., Reme-Saumon, M., N'Guyen, T.D., Lesaunier, F., Le Simple, T., Gamelin, E., Hery, M., Berlie, J.

“…From 1960 to 1986, 397 cases of non-metastatic male breast cancer (MBC) treated in 14 French regional cancer centres were reviewed. The median age was 64 years…”
Get full text

Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment by the French Epirubicin Study Group

“…To determine whether the duration and the dose of epirubicin modify the long-term outcome of patients with metastatic breast cancer (MBC). Four hundred…”
Get full text

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer by Namer, M, Soler-Michel, P, Turpin, F, Chinet-Charrot, P, de Gislain, C, Pouillart, P, Delozier, T, Luporsi, E, Etienne, P.L, Schraub, S, Eymard, J.C, Serin, D, Ganem, G, Calais, G, Maillart, P, Colin, P, Trillet-Lenoir, V, Prevost, G, Tigaud, D, Clavère, P, Marti, P, Romieu, G, Wendling, J.L

“…This comparative phase III trial of mitoxantrone+vinorelbine (MV) versus 5-fluorouracil+cyclophosphamide+either doxorubicin or epirubicin (FAC/FEC) in the…”
Get full text

Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial by By the French Adjuvant Study Group

“…To determine the influence of the epirubicin dose in operable node-positive breast cancer patients with factors of poor prognosis. Between April 1990 and July…”
Get full text

Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II) by Dumas, M, d'Athis, P, de Gislain, C, Escousse, A, Guerrin, J, Autissier, N

“…The disposition of cis-dichlorodiammineplatinum (CDDP) was evaluated in 8 patients with cancer. They received 80 mg/m2 of CDDP as a 20 min i.v. infusion…”
Get more information

Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case‐control study by Mignotte, Hervé, Lasset, Christine, Bonadona, Valérie, Lesur, Anne, Luporsi, Elisabeth, Rodier, Jean‐François, Cutuli, Bruno, Lasry, Serge, Mauriac, Louis, Granon, Claire, Kerr, Christine, Giard, Sylvie, Hill, Catherine, De Lafontan, Brigitte, De Gislain, Catherine, D'Anjou, Joëlle, Fondrinier, Eric, Lefeuvre, Claudia, Parache, Robert‐Michel, Chauvin, Franck

“…Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be…”
Get full text

Leucémies et états préleucémiques survenus après traitement d'un cancer du sein by CUTULI, B, JANVIER, M, GANEM, G, BAUME, D, LE MEVEL, A, LORTHORALY, A, DE GISLAIN, C, MARCHAL, C, CHEVELLE, C, LAUCHE, H, SERIN, D, DE LA ROCHEFORDIERE, A, JULIEN, J. P, ISAMBERT, N, ALZIEU, C, KERBRAT, P, DE LAFONTAN, B, VAN LEMMENS, L, CURE, H

Get full text

Role of Mdr phenotype in locally advanced breast cancer (LABC) treated with primary chemotherapy (CT1) by Coudert, B., Lizard, S., Arnal, M., Genne, Ph, Darut-Jouve, A., Bélichard, C., Arnould, L., Riedinger, J.M., Mayer, F., de Gislain, C., Fargeat, P.

Get full text

Influence of frusemide on cis-dichlorodiammineplatinum (II) pharmaco-kinetics by DUMAS, M, D'ATHIS, P, DE GISLAIN, C, LAUTISSIER, J. L, AUTISSIER, N, ESCOUSSE, A, GUERRIN, J

“…Cis-dichlorodiammineplatinum (CDDP) pharmacokinetics were evaluated in eighteen patients with cancer who received 80 mg/m2 CDDP as a 20 min infusion. One hour…”
Get full text

Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma by Mornex, F, Thomas, L, Mohr, P, Hauschild, A, Delaunay, M M, Lesimple, T, Tilgen, W, Nguyen, B B, Guillot, B, Ulrich, J, Bourdin, S, Mousseau, M, Cupissol, D, Bonneterre, J, de Gislain, C, Bensadoun, J R, Clavel, M

“…The main objective of this prospective multicenter randomised phase III study was to compare a combined regimen of fotemustine plus whole brain irradiation…”
Get full text

Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles by Riedinger, J M, Eche, N, Basuyau, J P, Daver, A, Touzery, C, Mayer, F, Coudert, B, Fargeot, P, Chauffert, B, de Gislain, C, Zanetta, S

“…Mathematical analysis of CA125 kinetics during first line chemotherapy allows calculation of various biologic parameters which are powerful indicators of the…”
Get more information

966 Feasibility of 5-FU therapeutic monitoring by Coudert, B., de Gislain, C., Beltramo, Riedinger, J.M., Mayer, F., Bruchon, Y., Dumas, M., Fargeot, P., Guerrin, J.

“…5-FV therapeutic monitoring was performed, in 26 patients with localized or disseminated epidermoïd tumour of various origin, during 64 chemotherapy cycles…”
Get full text

Endometrial carcinoma (EC) in women with breast cancer (BC) by Mignotle, H., Lesur, A., Luporsi, E., Rodier, J.F., Cutuli, B., Lasry, S., Mauriac, L., Granon, C., Kerr, C., Giard, S., Hill, C., De Lafontan, B., De Gislain, C., D’Anjou, J., Fondrinier, E., Lefeuvre, C., Lasset, C., Bonadona, V., Chauvin, F.

Get full text

Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) by Mignotte, H, Lasset, C, Bonadona, V, Lesur, A, Luporsi, E, Rodier, J F, Cutuli, B, Lasry, S, Mauriac, L, Granon, C, Kerr, C, Giard, S, Hill, C, de Lafontan, B, de Gislain, C, D'Anjou, J, Fondrinier, E, Lefeuvre, C, Parache, R M, Chauvin, F

“…Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be…”
Get full text

Leukemia and pre-leukemic conditions occurring after treatment of breast cancer by Cutuli, B, Janvier, M, de la Rochefordière, A, Julien, J P, Isambert, N, Alzieu, C, Kerbrat, P, de Lafontan, B, van Lemmens, L, Curé, H, Ganem, G, Baume, D, Le Mevel, A, Lorthoraly, A, de Gislain, C, Marchal, C, Chevelle, C, Lauche, H, Serin, D

“…The purpose of this study was to determine the clinical and prognostic features of leukemias and preleukemic states, whatever the mode of development, observed…”
Get full text

1021 Ductal carcinoma in situ (DCIS) of the male breast: Analysis of 23 cases by Cutuli, B., Velten, M., Lacroze, M., Campana, F., Dilhuydy, J.M., Marchal, C., de la Fontan, B., Resbeut, M., Graic, Y., Tortocheaux, J., de Gislain, C., Moncho, V., Cuillere, J.C., N’guyen, T.D., Hery, M., Lesimple, T., Reme-Saumon, M., Lesaunier, F., Gamelin, E., Berlie, J.

“…From 1960 to 1990, 581 cases of male breast cancer (MBC) were reviewed in 19 Cancer Institutes in France. 23 (4%) were pure DCIS. The median age was 56.5 years…”
Get full text

Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin by Coudert, B, De Gislain, C, Beltramo, J L, Guigues, B, Mayer, F, Bruchon, Y, Riedinger, J M, Fargeot, P, Dumas, M, Guerrin, J

“…Therapeutic monitoring of 120 hours continuous 5-fluorouracil associated with cisplatin. For 31 patients treated by continuous 5-fluorouracil with cisplatin, a…”
Get more information

Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen by Cappelaere, P, Fournier, C, Rolland, F, Meeus, L, Domenge, C, Krakowski, I, De Gislain, C, Chauvergne, J, Dufour-Esquerre, F, Pion, J M, Hecquet, B

“…The aim of this study was to determine the value of haematological counts at the 4th day of a chemotherapy cycle, in order to foresee neutro and/or…”
Get more information

Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination by Cappelaere, P, Hecquet, B, Rolland, F, Meeus, L, Domenge, C, Krakowski, I, De Gislain, C, Chauvergne, J, Dufour-Esquerré, F, Carde, P

“…Eighty-four patients with locally advanced, non metastatic squamous cell carcinoma of head and neck or esophagus, were included in a multicentric double-blind…”
Get more information